Atypical antipsychotic agents for the schizophrenia prodrome: Not a clear first choice
| Autor: | Stefan P. Kruszewski, Richard P. Paczynski |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Preventive strategy business.industry medicine.drug_class Health Policy Public Health Environmental and Occupational Health Atypical antipsychotic General Medicine medicine.disease Prodrome Clinical research Current practice Schizophrenia Intervention (counseling) Medicine business Psychiatry Psychotic illness |
| Zdroj: | International Journal of Risk and Safety in Medicine. 20:37-44 |
| ISSN: | 0924-6479 |
| Popis: | Pharmacologic intervention at the earliest stages of suspected psychotic illness is an intuitively appealing concept and a logical extension of the current approach to many other diseases of the central nervous system. Atypical antipsychotic agents (ATAPs) seem to be a reasonable choice for early intervention because existing pre-clinical data suggest that they have pharmacologic properties which might confer 'neuroprotection'. However, a critical analysis of the results of structured clinical investigations which have explored the use of ATAPs for new-onset psychotic symptoms raises safety concerns and does not support pre-medication in this setting as a preventive strategy. Caution in current practice is therefore appropriate, underscoring the need for much additional clinical research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|